Malignant Neoplasms of Lip Oral Cavity and Pharynx Not Yet Recruiting Phase 1 Trials for Lenvatinib (DB09078)

IndicationStatusPhase
DBCOND0081505 (Malignant Neoplasms of Lip Oral Cavity and Pharynx)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02915172Lenvatinib and Capecitabine in Patients With Advanced MalignanciesTreatment